MedTrace Logo

Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

NCT03373903 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 652

Last updated 2018-05-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.

Conditions

  • Respiratory Tract Infections

Interventions

OTHER

Placebo

oral

DRUG

BEZ235

oral

DRUG

BEZ235 plus everolimus (RAD001)

Oral

Sponsors & Collaborators

  • Restorbio Inc.

    lead INDUSTRY

Principal Investigators

  • Sarb Shergill, PhD · Restorbio Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2018-05-03
Completion
2018-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03373903 on ClinicalTrials.gov